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ABSTRACT 
 
Objective: To compare intravenous iron sucrose with oral iron in treatment of severe iron deficiency 
anaemia in pregnant women presenting at Institute of Kidney Disease and Research Centre. The 
study was carried out in the department of Obstetrics and Gynaecology at Institute of Kidney Disease 
and Research Centre over a period of six months from 02-02-2010 TO 2-08-2010.  
Methodology: 50 cases with proven iron deficiency with Hb ≤7 gm/dl were included in the study. 
Total iron deficit was calculated using a standard formula. Target haemoglobin was 11 gm %. Iron 
sucrose was administered by intravenous infusion. Haemoglobin was repeated 1, 2, 3, and 4 weeks 
after the last dose of Intravenous Iron sucrose.  
Results: Anthropometric and biologic data for mothers in i.v. sucrose and oral iron groups  was 
similar. Distribution of cases by economic status showed, 21 patients (42.0%) belonged to lower class, 
20 patients (40%) belonged to middle class and 09 patients (18%) were of upper class.) Target 
haemoglobin levels were achieved in 4 weeks time in 19 (76%) patients in iron sucrose group as 
compared to 08 (32%) of patients in oral iron group .There was significant improvement in the 
various haematological parameters in iv sucrose group as compared to patients in oral iron group. 
There were no significant allergic reactions in iv sucrose group.  
Conclusion: This study has shown a significant improvement in anaemia in the iron sucrose group. 
Patients achieved the target of 11 gm %. Intravenous iron therapy is safe, convenient and more 
effective then oral iron therapy in pregnancy and is well tolerated. 
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INTRODUCTION 
In underdeveloped countries, anaemia is a major 
contributory factor to maternal morbidity and 
mortality1. According to WHO about 50 per cent 
of women of fertile age have iron deficiency 
anaemia2.  In India National Family Health 
Survey -II (1998) shows that 54% women in rural 
and 46% women in urban areas are anemic. . 
Inadequate antenatal care along with lack of 
knowledge of dietary needs of pregnant woman, 
and overall poor socioeconomic conditions are 
all responsible for this in our country3. 
According to WHO4 anaemia is defined as 
“haemoglobin less than 11gm/dl and a 
haematocrit of less than 0.33  . Most women 
begin their pregnancy with partially or 
completely depleted iron reserves. Thus, the 
severity of the anaemia is inversely related to 
the amount of iron reserves5. During pregnancy, 
there is a great demand for iron to meet the 
requirement of red cells mass expansion in the  
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mother fetal and placental blood and blood loss 
at delivery6  . Anaemia in the most common 
medical disorder in pregnancy and is 
responsible indirectly for 40-60% of the maternal 
death in developing countries7. It affects about 
18% of pregnant women in developed and 35-
75% of pregnant women in developing 
countries8.  
Iron-deficiency anaemia is a major health 
problem worldwide, but responds well to iron 
supplementation. New approaches are leading 
to more effective management of this condition. 
The introduction of second-generation i.v. iron 
formulations, including iron sucrose and ferric 
gluconate, was clearly an improvement over i.v. 
iron dextran. These formulations proved to be 
effective in the management of IDA and are not 
associated with the serious allergic reactions 
encountered with i.v. iron dextrans. An 
important advantage of i.v. iron over oral iron is 
that it may bypass hepcidin actions by directly 
loading transferrin and making iron available to 
macrophages. Iron deficiency is usually 
suspected in at-risk patients with declining 
haemoglobin (Hb) levels and then confirmed by 
measuring serum ferritin levels and transferrin 
saturation. Patients are commonly prescribed 
oral iron preparations because of convenience 
and low cost. However, the efficacy of these 
agents is limited by their reduced absorption 
rate and gastrointestinal side-effects and 
compliance. 
We therefore evaluated the efficacy and safety of 
intravenous iron sucrose as compared with oral 
iron sulfate for the treatment of iron deficiency 
anemia (IDA) in patients with anemia.  
 
METHODOLOGY 
Approval of institutional ethics committee was 
taken before starting the trial.A randomized, 
retrospective, open-label, single center study 
was performed in 50 pregnant patients >18 
years old, > 24 weeks gestation, with anemia Hb 
≤7 gm/dl and transferrin saturation ≤10% 
and/or serum ferritin concentrations ≤15 
microg/L. They were randomized into two 
groups.  Group A consisted of 25 women who 
received i.v. a total amount of iron sucrose. Iron 
sucrose was given by intravenous injection on 
alternate day according to the iron deficit 
calculated for each individual patient, 200mg 
elemental iron diluted in 100ml of 0.9% normal 
saline infusion, initially given at 8-12 drops/min 
for 15-30 minutes and patient was monitored for 
any sign of allergic reaction. Later rest of 
infusion was given at 36 drops/minute over 2 
hours. 
 In the intravenous group (IV group), the total 
iron sucrose dose to be administered was 
calculated from the formula: Body Weight in 
kilograms (before pregnancy) × (Target 
haemoglobin i.e11gm/dl – Actual hemoglobin) 
× 0.24 + 500 mg; target hemoglobin in grams per 
litre was set at 11 g/dL because of physiologic 
hemodilution during pregnancy; actual 
hemoglobin in grams per litre was the patient’s 
hemoglobin level on inclusion; 0.24 was a 
correction factor that take into account the 
patient’s blood volume, estimated at 7% of body 
weight and hemoglobin iron content; 500 mg is 
the quantity of stored iron in adults.12 This 
gives amount of elemental iron needed. This 
dose was given in 6 slow intravenous injections 
(on days 1, 3, 5, 7, 9, and 10). A maximum of 200 
mg of iron (2 ampules) was administered using 
a small catheter, into a vein of sufficient caliber. 
For the first injection, 25 mg was injected very 
slowly and the patient was monitored during 15 
minutes for signs of intolerance such as an 
anaphylactic reaction or hypotension. . This 
ensured that all incidents were noted, such as 
arterial hypotension during injections, 
tachycardia, hyperthermia, arthralgia, 
abdominal pain, a sensation of chest tightness, 
headache, vertigo, digestive problems, skin 
eruption, allergic reactions, and a strange taste 
during injection. Iron was administered by slow 
infusion. Treatment was stopped either after 
administration of the calculated dose or once the 
haemoglobin level had reached 11 g/dL.In 
addition fifteen milligrams of folic acid was 
systematically associated with the treatment to 
prevent an eventual folic acid deficiency and to 
eliminate the influence of such a deficiency on 
the results. Additional oral or IM form of iron 
administration of iron was excluded during the 
4 weeks of study. 
Haemoglobin and haematocrit were repeated 1, 
2, 3, 4 weeks after the last dose of intravenous 
iron. Other hematological parameters were 
repeated 4 weeks after completion of treatment. 
Group B consisted of 25 women, who received 
three 200 mg iron sulphate tablets 1 t.d.s 
containing 60 mg of elemental iron (i.e., a total 
of 180 mg of elemental iron per day for 4 weeks) 
Patients were required to carefully note 
treatment compliance on a calendar provided  
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for that purposeThe 2 groups were monitored 
both clinically and biologically. On each visit, 
adverse reactions linked with or likely to be 
linked with the treatment were identified 
  Demographic data were matched. A specially 
d e s i g n e d  p r o f o r m a  w a s  u s e d  t o  c o l l e c t  t h e  
demographic information including name, age 
and gestational age. Purpose of study with 
beneficial effects as well as side effects of drug 
was explained to each eligible patient and 
informed consent was taken from each patient. 
Target Hb was 11gm/dl. 
Inclusion Criteria- Women who are >24 weeks 
of gestation with Hb≤7gm/dl, who agree to 
participate in this study in writing.  
Exclusion Criteria- From the study we excluded 
cases with a diagnosis of placenta previa, 
placenta abruption, pre-eclampsia and clotting 
disorders Patients who have participated in 
another clinical study in recent 3 months, or 
shown intolerance or hypersensitivity to iron 
therapy ,hemolytic anemia, hemoglobinopathies 
(thalassemia, sickle cell) , bleeding tendency, 
hypersplenism , chronic heart failure, Class II-IV 
heart disease, uncontrolled arterial hypertension 
(DBP  ≥ 115mmHg), deep vein thrombosis, 
thrombocytosis, chronic renal disease, severe 
renal failure patients (2.5 times or more higher 
plasma creatinine level than high limit of normal 
state) , with severe liver dysfunction (2.5 times 
or more higher AST or ALT than high limit of 
normal state)e.g. cirrhosis, viral hepatitis 
,patients with doubled or more CK level than 
high limit of normal state ,asthma, seizure 
disorder ,haemochromatosis, haemosiderosis. 
Primary Outcome Measures: Proportion of 
patients attaining target Hb of ≥ 11gm/dl. 
Secondary Outcome Measures: Change of 
plasma hemoglobin level, target Hb 
achievement rate (11g/dL), transferrin 
saturation (%), ferritin (ng/mL), MCV (fl) in 4 
weeks time. 
Statistical Analysis: Statistical analysis was 
performed using the Statistical Package for the 
Social Sciences (SPSS version 12.0). Continuous 
variables were compared using Mann Whitney 
U-test. Chi square test of Fisher exact test were 
used to assess the effect of change in differences 
in categorical variables. Data Values are 
expressed as mean ± SD, count (%age) & p < 
0.05 is considered to be statistically significant. 
The quantitative variables like age were 
presented by calculating Mean±SD. The 
qualitative variables like economic class (lower, 
middle, upper) and efficacy of drug (yes/no) 
was presented by calculating frequency and 
percentages Difference between the two groups 
for the primary end point were analyzed by 
using chi-square test. Student’s T test was 
applied for secondary end point. 
 
RESULTS 
On inclusion, the two groups were comparable 
in terms of both anthropometric and biologic 
data (Table 1, 2, and 3). All patients reported 
regular use of iron tablets for 2 weeks before 
study entry. Before treatment, iron-deficiency 
anemia (ferritin <15 µg/L) was confirmed in all 
patients. The groups did not differ in baseline 
hematologic characteristics, iron status, or time 
of treatment initiation (approximately 28 weeks 
gestation; Table 1). 
 
Table 1: Anthropometric and biologic data for mothers in IV Sucrose and Oral iron groups (n=25) 
Parameters  IV Sucrose  Oral Iron  P Value 
Mean Age (Years)  28.1 ± 5.36  27.8 ± 5.28  0.838 
Mean Weight (Kg)  54.5 ± 3.45  55.9 ± 2.07  0.108 
Parity (Primi/ Multi)  10 /15 (40%/60%)  08 /17 (32%/68%)  0.556 
Mean gestational age (wks)  28.2 ± 2.30  28.87 ± 2.40  0.165 
Mean Haemoglobin (gm/dl)  6.27 ± 0.48  5.95 ± 0.62  0.087 
Mean PCV (%)  18.8 ± 1.46  17.8 ± 1.86  0.087 
Mean Ferritin (µg/l)  9.44 ± 3.01  10 ± 1.9  0.375 
 
Hematologic response: While a comparable 
increase in hemoglobin was observed for both 
administration routes (mean increase 1.15 
gm/dL in the intravenous group vs 0.88 g/dL in 
the oral group in the first week of treatment. 
Both groups showed an immediate reticulocyte 
response and continuous increase in hematocrit. 
i.v. iron sucrose had greater increases in  
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hematocrit (%) from first week of treatment 
22.2±1.74 as compared to 20.4±2.49 in oral iron, 
which is statistically significant (P<0.0006) 
(Table-2). 
Table 2: Change in Haematological Parameters over 4 weeks (n=25) 
Group name  Levels  IV Sucrose  Oral Iron  P-Value 
Hb (gm/dl)  Baseline 6.27±0.48  5.94±0.62  0.087 
One week  7.42±0.58  6.82±0.83  0.006* 
Two week  8.62±0.60  7.64±1.21  0.002* 
Three week  9.9±0.66  8.6±0.79  0.000004* 
Four week  11.3±0.70  10.26±1.077  0.0006 * 
Hematocrit (%)  Baseline 18.8±1.46  17.8±1.76  0.087 
One week  22.2±1.74  20.4±2.49  0.006* 
Two week  25.8±1.81  22.9±3.64  0.002* 
Three week  29.7±2.0  25.8±2.38  0.000004* 
Four week  33.9±2.11  30.77±3.23  0.0006 * 
 
Target hemoglobin level of 11.0 g/dl was 
reached in 4 weeks time in i.v. iron sucrose. 
None of the patients in oral iron had target 
hemoglobin level of 11.0 g/dl in 4 weeks time 
with mean hemoglobin value of 9.73±1.23 g/dL 
at the end of 4 weeks, which is statistically 
significant (P<0.00002) (Table-4). 
Iron status. Ferritin level (µg/l ), transferrin 
saturation(%) ,MCHC (gm%), MCV(fl), 
Hypochromasia (%) on peripheral smear 
increased continuously until the end of therapy 
in both groups and was higher in i.v. iron 
sucrose which is statistically significant(Table-3).  
 
Table 3: Change in various Haematological Parameters (n=25) 
Group name  Levels  IV Sucrose  Oral Iron  P-Value 
Hb (gm/dl)  Baseline 6.27±0.48  5.94±0.62  0.087 
Four week  11.3±0.70  10.26±1.077  0.0006 * 
Hematocrit (% )  Baseline 18.8±1.46  17.8±1.76  0.087 
Four week  33.9±2.11  30.77±3.23  0.0006 * 
Ferritin (µg/l )  Baseline 9.44±3.01  10.0±1.90  0.375 
Four week  295.5±45.1  160.8±33.1  <0.0001 * 
Trasnferrin Saturation 
(%) 
Baseline 7.24±1.73  8.08±1.15  0.070 
Four week  29.3±4.55  22.2±1.56  <0.0001* 
Reticlocyte Count (%)  Baseline 1.69±0.14  1.63±0.16  0.292 
Four week  4.27±0.18  4.2±0.19  0.209 
MCHC (gm %)  Baseline 26.0±1.73  25.6±2.06  0.574 
Four week  33.1±0.97  32.08±1.41  0.009 * 
MCV(fl)  Baseline 71.28±0.97  70.1±2.93  0.108 
Four week  93±1.13  85.8±3.97  <0.0001* 
Hypochromasia (%)  Baseline 46±3.82  45.6±1.35  0.357 
Four week  2.37±0.14  3.01±0.95  0.001* 
 
Nineteen (76%) women in i.v. iron sucrose had 
normal antepartum hemoglobin levels (>11.0 
g/dL) as compared to 8 (32%) women in oral 
iron, which is statistically significant (P<0.002) 
(Table-4). 
None of the women needed additional 
antepartum or postpartum blood transfusion. 
Two i.v. iron sucrose patients (8%) had grade I 
mild to moderate allergic reactions settled with 
an anti-allergic drug but not requiring 
discontinuation of the infusion. None of the 
patients had grade-II severe reaction threatening 
the patient’s life and requiring discontinuing of 
infusion.  
Table 4: Change in level of Haemoglobin 
(n=25) at the end of four weeks 
Hb (gm/dl)   IV 
Sucrose 
Oral 
Iron 
P-
Value 
9-10 (gm/dl)  02(08%) 12(48%) 0.002* 
10-11 (gm/dl)  04(16%) 05(20%) 0.713 
>11(gm/dl)  19(76%) 08(32%) 0.002* 
Data are expressed as mean ± SD. * P < 0.05 
indicates Statistical significance.  
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Intractable gastrointestinal adverse events 
caused permanent study drug discontinuation 
in four patients (16%) ( Table 5) receiving iron 
sulfate, whereas none patient had to be 
withdrawn because of side effects due to iron 
sucrose. 
 
Table 5: Adverse effects of iron treatment (n=25) 
Adverse Effects  IV Sucrose  Discontinuation 
of drug 
Oral Iron  Discontinuation 
of drug 
Nausea  - -  02  (8%)  - 
Headache  - -  -  - 
Diarrhoea  - -  05  (20%)  02(8%) 
Constipation   -  02  (8%)  - 
Anaphylaxis Grade1  02 (8%)  -  -  - 
Anaphylaxis Grade 2  -  -  - 
Gastritis  - -  03  (12%)  02(8%) 
Fever  01 (4%)  -  -  - 
Arthritis  01 (4%)  -  -  - 
Altered Taste  04 (16%)  -  03 (12%)  - 
Thrombophlebitis  01 (4%)  -  -  - 
 
Safety: There were no serious reactions to iron 
sucrose. Four (16%) patients reported a metallic 
taste, and 1(4%) reported fever. No hypotensive 
or hypertensive responses were seen during or 
after therapy. One (4%) patient developed 
thrombophlebitis but no thromboembolic 
complications were seen. A clear increase in 
hemoglobin was observed in the 2 groups, rising 
from 6.27±0.48 g/dL to 11.3±0.70 /dl on day 28 
in the i.v. sucrose group and from 5.94±0.62 
g/dL to 10.26±1.077 g/dL on day 28 in the oral 
iron group. 
In 4 weeks time , at the end , mean haemoglobin 
increase was more in the i.v. sucrose group 
(5.03±0.22g/dl ) than in oral iron group, ( 
4.32±9.45gr/dl) Which is statistically significant 
(Table-IV) (P <0.0006) and also the increase in 
ferritin levels was more in i.v. sucrose group 
(286.06 ±41.99) ) than in oral iron group 
,(150.8±31.10). Which is statistically significant 
(Table4) (P <0.0001).  
 
DISCUSSION 
Iron-deficiency anaemia is a major health 
problem worldwide, but responds well to iron 
supplementation. New approaches are leading 
to more effective management of this condition. 
Iron deficiency is usually suspected in at-risk 
patients with declining haemoglobin levels and 
then confirmed by measuring serum ferritin 
levels and transferrin saturation. Iron deficiency 
anemia during pregnancy is common and 
deserves special attention because of its 
potential consequences. In practice, physicians 
are often faced with poor compliance, justified 
by digestive side effects that can lead to 
worsening anemia. In these cases the parenteral 
forms of administration are indicated, as well as 
those in which the oral treatment is ineffective. 
Except for bone marrow biopsy, serum ferritin is 
best indicator for assessment of iron stores in the 
non-pregnant women2, 9. Treatment of iron-
deficiency anemia has included oral iron, 
intramuscular iron, iron dextran, recombinant 
erythropoietin and blood transfusion10, 11. 
However, most of these have their 
disadvantages. Even patients who respond well 
to oral iron therapy require a long time (months) 
to reach target Hb compared with weeks 
required in case of treatment with parenteral 
iron.. The use of intramuscular iron preparations 
is discouraged because of pain, irregular 
absorption and staining. 
Blood transfusion may improve symptomatic 
anemia quickly but there is a risk of transfusion 
reaction and blood born infection transmission12.  
The responsible constellation factors producing 
iron deficiency anaemia generally precedes the 
pregnancy, including diet poor in iron content 
coupled with menstrual losses and a rapid 
succession of pregnancies in which 
supplemental iron was not provided. A random, 
prospective, open study conducted in France by 
Bayomeu et al13 involving 50 patients at 6 month 
of gestation to compare intravenous iron sucrose  
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versus oral route showed an increase in 
haemoglobin from 9.6±0.7 g/dl to 11.11±1.3g/dl 
after 4 weeks of treatment (P<0.001). The results 
of this study regarding the use of iron sucrose 
are comparable to current study. In a study 
conducted at Aga Khan Hospital14 for women 
and children Karachi on 60 pregnant women at 
12-34 weeks gestation with iron deficiency 
anaemia. I/V iron sucrose were compared to 
iron sorbitol. Mean increase of 2.6g/dl Hb was 
seen in iron sucrose group15. 
In another study carried out by Raja et a1 at 
Rawalpindi on intravenous iron sucrose 
complex therapy in iron deficiency anaemia in 
pregnant women. Fifty pregnant women 
between 16-32 weeks of gestation with 
haemoglobin of 8 gm/dl were included. Results 
showed mean Hb level increased from 7.5 to 
11gm/dl 11. In present study mean Hb before 
therapy was 6.27±0.48 in iron sucrose group and 
after therapy 11.3±0.70 (P<0.00002) in 4 weeks 
time. Our results are consistent with the study of 
Raja et al. 
This indicates that as the severity of anaemia 
increase the response to iron sucrose therapy 
becomes excellent. Because as soon as tissues 
iron deficiency is established, the serum 
Transferrin concentration increases in direct 
proportion to degree of iron deficiency 3. Like 
most of the other studies there were no major 
adverse reactions noted in any patient in our 
study.  
Present study shows that of i.v iron sucrose 
significantly (P<0.00002) increase haemoglobin 
levels within 4 weeks. There were no major 
adverse reactions. 
Intravenous iron is effective in achieving target 
Hb of 11g/dl in 80% of patients. For iron 
defined patients, intravenous iron is 
incorporated into hemoglobin within 3 to 4 
weeks by erythropoiesis 16. Intravenous iron 
treated iron deficiency anemia of pregnancy and 
restored iron stores faster and more effectively 
than oral iron, with no serious adverse reaction 
7.  
Conclusion: Intravenous iron therapy is safe, 
convenient and more effective then oral iron 
therapy in treatment of iron deficiency anemia 
during pregnancy. Limitations with intravenous 
iron replacement include the need for medical 
supervision in the setting of limited healthcare 
resources; the need for patients to take multiple 
days off work and the cost of IV iron. 
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